GLP-1 Patches: Do They Work and What Is in Them?
GLP-1 patches are stick-on products sold online with the name of a popular weight loss drug class. The labels we read listed no GLP-1 drug. They list herbs such as berberine, plus vitamins. None of the five named a study of the patch itself. The US Federal Trade Commission lists claims of substantial weight loss from products worn or rubbed on the skin as false.
The short version
- No drug inside: 0 of the 5 labels we read listed semaglutide, tirzepatide or any GLP-1 drug.
- Too big for skin: the GLP-1 drugs weigh 7.5 to 126 times the size limit for soaking through intact skin.
- On the record: the FTC guide says "nothing you wear or apply to the skin can cause substantial weight loss."
Most pages for this search are shops or short explainers. This one adds the drug weights from the FDA labels, our own read of five patch labels, and the regulator records with links. For pills and shots people compare, see our Ozempic alternatives guide.
Sources: Peptides Vietnam label check, 23 October 2026: five GLP-1 patch product pages read by us, counts from our own notes.; US Federal Trade Commission, "Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims" (January 2014, read 23 October 2026): the guide covers patches, creams and wraps, and says nothing worn on the body or rubbed into the skin can cause substantial weight loss, and names patches among its examples.; openFDA Drugs@FDA search run 23 October 2026 for semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, albiglutide and orforglipron: 32 application records, with routes listed as subcutaneous, injection or oral, and no skin or transdermal route.
What is in a GLP-1 patch?
The patches are sold as supplements. Their labels list plant extracts, B vitamins and amino acids. Berberine, a yellow compound from several plants, shows up most. Cinnamon, pomegranate, green tea, gymnema, L-glutamine and chromium are also common.
Pharmacy researchers in Connecticut found the same pattern in 2026. The authors looked at 24 patch products and one gel. Berberine, glutamine, cinnamon and pomegranate were listed most. None posted a certificate of analysis, and many lacked the FDA statement that labels need when they make a structure or function claim.
The same authors raise a legal point. US law defines a dietary supplement as something you swallow. A patch is not swallowed, so they argue these products break the law as sold.
Sources: White CM, Tai Z, Nuzi K. "Transdermal “Natural GLP-1” Dietary Supplements Violate Law and Place Patients at Risk." Annals of Pharmacotherapy, 2026. PMID 41480958.; Cleveland Clinic Health Essentials, "Do GLP-1 Patches Actually Work?" (read 23 October 2026): unknown contents, the risk of unlisted ingredients, and skin reactions to the patch itself.
What we found on five real patch labels
On 23 October 2026 we read the product pages of five patches that come up when you search for GLP-1 patches. We only read them. We bought nothing and signed in nowhere. Two big shop pages showed a robot check, so we left them out. We name no brand here.
| Patch | Where we read it | GLP-1 wording | Listed ingredients |
|---|---|---|---|
| Patch 1 | US brand, own site | A menu link called GLP-1 patches opens this berberine patch | berberine, pomegranate, cinnamon, B vitamins, L-glutamine, chromium |
| Patch 2 | US brand, own site | None on the product page | berberine, green tea, cinnamon, L-glutamine, chromium |
| Patch 3 | US brand, own site | None on the product page | berberine, pomegranate, cinnamon, gymnema, B vitamins, L-glutamine, chromium picolinate |
| Patch 4 | Patch brand, own site | Product name says upgraded GLP-1 | berberine, pomegranate, cinnamon, B vitamins, L-glutamine, chromium |
| Patch 5 | Australian brand, own site and a pharmacy listing | The pharmacy listing calls the herbs GLP-1 supportive | berberine, L-carnitine, green tea, 5-HTP, fucoxanthin, gymnema, red orange, chromium picolinate |
| What we checked | How many of 5 |
|---|---|
| Listed berberine | 5 of 5 |
| Listed chromium | 5 of 5 |
| Listed semaglutide, tirzepatide or any GLP-1 drug | 0 of 5 |
| Tied the product to the words GLP-1 | 3 of 5 |
| Printed an amount for each ingredient | 3 of 5 |
| Carried the US line saying the FDA has not evaluated its claims | 3 of 5 |
| Named a published study of the patch itself | 0 of 5 |
The words GLP-1 did not match what was inside. Three of the five used the term, yet none listed a GLP-1 drug. One menu link labelled GLP-1 patches simply opened a berberine patch. Two brands pointed to studies of single ingredients, taken by mouth, not to any study of the patch.
This is our own small snapshot from one day, not a survey of the market. The US statement about the FDA is not required on the Australian product.
Sources: Peptides Vietnam label check, 23 October 2026: five GLP-1 patch product pages read by us, counts from our own notes.
Why can a GLP-1 drug not soak through intact skin?
Size is the main reason. The outer layer of skin is a tight barrier. A well known 2000 paper in Experimental Dermatology set out the 500 Dalton rule: a molecule needs to weigh less than about 500 Daltons to pass the outer layer of intact skin on its own. That is passive delivery, with nothing piercing the skin. Every drug used in skin patches at that time met the rule.
GLP-1 drugs are small proteins, far heavier than that. We took each weight from its FDA label or PubChem record and divided it by 500. The table shows the result.
| Molecule | Weight (Daltons) | Times the 500 limit | Under the limit? | Weight from |
|---|---|---|---|---|
| Semaglutide (Ozempic, Wegovy) | 4,113.58 | 8.2x | No | FDA label |
| Tirzepatide (Mounjaro, Zepbound) | 4,813.53 | 9.6x | No | FDA label |
| Liraglutide (Victoza) | 3,751.2 | 7.5x | No | FDA label |
| Dulaglutide (Trulicity) | about 63,000 | 126.0x | No | FDA label, approximate |
| Berberine | 336.4 | 0.7x | Yes | PubChem |
| Chromium picolinate | 418.3 | 0.8x | Yes | PubChem |
| EGCG (green tea) | 458.4 | 0.9x | Yes | PubChem |
| L-glutamine | 146.14 | 0.3x | Yes | PubChem |
Method: weight divided by 500, rounded to one decimal place. The GLP-1 drugs land between 7.5 and 126 times over the limit. The patch herbs are small enough, but passing the size test proves nothing on its own. A PubMed search we ran on 23 October 2026 for berberine with transdermal or patch gave 123 records. We read the titles of the 33 tagged as human research. None measured berberine in the blood after a patch was worn.
Microneedle research is a separate thing. These patches carry rows of tiny needles that pierce the outer layer, so the size rule for passive delivery does not apply to them in the same way. A 2024 study in Advanced Therapeutics and a 2026 study in the International Journal of Pharmaceutics both tested semaglutide microneedles in rats. Neither is a product sold to the public, and the labels we read describe plain stick-on patches.
The FDA record agrees. We searched the Drugs@FDA database for all eight GLP-1 drugs it lists, from semaglutide to orforglipron. The 32 records list shots and tablets only. Not one lists a skin route.
Sources: Bos JD and Meinardi MM, Experimental Dermatology, 2000: the paper that proposed the 500 Dalton limit for skin. PMID 10839713.; Ozempic (semaglutide) injection, US prescribing information on DailyMed (read 23 October 2026): molecular weight and the elimination half-life of about one week.; Mounjaro (tirzepatide) injection, US prescribing information on DailyMed (read 23 October 2026): molecular weight of the molecule.; PubChem, berberine, CID 2353, molecular weight 336.4 (read 23 October 2026); PubChem, chromium(III) picolinate, CID 151932, molecular weight 418.3; PubChem, epigallocatechin gallate (EGCG), CID 65064, molecular weight 458.4; PubChem, L-glutamine, CID 5961, molecular weight 146.14; openFDA Drugs@FDA search run 23 October 2026 for semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, albiglutide and orforglipron: 32 application records, with routes listed as subcutaneous, injection or oral, and no skin or transdermal route.; PubMed search run 23 October 2026: berberine AND (transdermal OR patch OR patches) gave 123 records. We read the titles of the 33 tagged as human research; none measured berberine in the blood after a patch was worn.; Singh P and colleagues. "Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity." Advanced Therapeutics, 2024. PMID 39429250. The full text says it was tested in rats.; Cheng X and colleagues. "Poly(vinyl alcohol) dissolving microneedles for transdermal semaglutide delivery and anti-obesity therapy in rats." International Journal of Pharmaceutics, online 21 October 2026. PMID 42906796, record checked on PubMed 23 October 2026. An animal study.
How much berberine does one patch hold?
Three of the labels printed a berberine amount. We set those beside the amount given by mouth in a 2008 human trial of berberine in type 2 diabetes, published in Metabolism. Our script divided each label amount by the trial amount for one day.
The patch labels we read on 23 October 2026 and the 2008 Metabolism trial give these figures:
Per patch, label: 7 mg, 8.75 mg and 9.6 mg. Trial, by mouth: 0.5 g three times a day, or 1,500 mg a day. Each patch label equals 0.47%, 0.58% and 0.64% of that daily trial amount.
Disclaimer: these are label figures copied from seller pages and a trial amount from one study, set side by side for comparison only. They are not a dose for anyone. The trial tested berberine swallowed as a pill, not worn on the skin.
So even before the skin barrier, each patch label holds only a small share of what that trial used. How much of it reaches the blood through skin is not known. For what the research on berberine itself shows, see our berberine guide.
Sources: Yin J, Xing H, Ye J. "Efficacy of berberine in patients with type 2 diabetes mellitus." Metabolism, 2008. PMID 18442638. A human trial of berberine taken by mouth.; Peptides Vietnam label check, 23 October 2026: five GLP-1 patch product pages read by us, counts from our own notes.
What have the FTC and FDA said?
The FTC polices ads in the US. In 2014 it published Gut Check, a guide that helps media outlets spot false weight loss ads. It names seven claims that are false. One is that a product "causes substantial weight loss by wearing a product on the body or rubbing it into the skin." The guide gives patches, creams, wraps and body belts as examples.
The agency has acted on patches before. In August 2007 it said one patch maker and its owner would pay $180,000 and were banned from selling weight loss patches. The order also barred claims that a product worn or rubbed on the skin works for weight loss.
The FDA page on unapproved GLP-1 drugs says those products skip its review for safety, quality and whether they work. It has sent warning letters to sellers of illegal semaglutide and tirzepatide. A patch that truly held one of those drugs would fall under those rules.
Sources: US Federal Trade Commission, "Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims" (January 2014, read 23 October 2026): the guide covers patches, creams and wraps, and says nothing worn on the body or rubbed into the skin can cause substantial weight loss, and names patches among its examples.; US Federal Trade Commission press release, "Weight-Loss Patch Manufacturer Banned From Selling Weight-Loss Patches, Will Pay $180,000" (20 August 2007, read 23 October 2026): the order bars claims that a product worn or rubbed on the skin works for weight loss.; US FDA drug safety page on unapproved GLP-1 products for weight loss (page dated 1 October 2026; we read it 23 October 2026): unapproved versions skip FDA review for safety, effectiveness and quality, and the agency has sent warning letters over illegally sold semaglutide and tirzepatide.
What are the known risks?
- A skin reaction to the patch glue or its contents, called contact dermatitis.
- Hidden or missing ingredients. The FDA says it does not test dietary supplements before they are sold to consumers.
- Money and time spent on a product whose label, in our check of five, named no study of the patch.
- Putting off a talk with a doctor about the approved options.
The 2026 review also found buyer comments that described no effect or side effects for several products. Those are reports from buyers, not trial data. This list is not a diagnosis. It is what doctors and researchers have flagged.
Sources: Cleveland Clinic Health Essentials, "Do GLP-1 Patches Actually Work?" (read 23 October 2026): unknown contents, the risk of unlisted ingredients, and skin reactions to the patch itself.; White CM, Tai Z, Nuzi K. "Transdermal “Natural GLP-1” Dietary Supplements Violate Law and Place Patients at Risk." Annals of Pharmacotherapy, 2026. PMID 41480958.; US FDA, "Questions and Answers on Dietary Supplements" (content current as of 27 August 2026, read 23 October 2026): the FDA does not test dietary supplements before they are sold to consumers.
How do the patches compare with the approved drugs?
The approved GLP-1 drugs are copies of a gut hormone, built to last. On the Ozempic label, the half-life of semaglutide is given as roughly one week. It is given as a weekly shot or a daily tablet under a prescription. None of the five patch labels we read lists any of it.
Researchers are working on real skin delivery. A 2026 study loaded semaglutide into tiny dissolving needles and tested them on rats. Those needles pierce the top layer of skin, which a sticker cannot do. It is early animal work. The Drugs@FDA search we ran lists no skin route for any approved GLP-1 drug.
If you read about pills and powders sold the same way, our guide to GLP-1 supplements and what studies show covers them. For the drug class itself, start with our GLP-1 guide.
Sources: Ozempic (semaglutide) injection, US prescribing information on DailyMed (read 23 October 2026): molecular weight and the elimination half-life of about one week.; Cheng X and colleagues. "Poly(vinyl alcohol) dissolving microneedles for transdermal semaglutide delivery and anti-obesity therapy in rats." International Journal of Pharmaceutics, online 21 October 2026. PMID 42906796, record checked on PubMed 23 October 2026. An animal study.
Common questions
Do the GLP-1 patches really work?+
We found no study showing they work, within what we checked. None of the five labels we read named a study of the patch or listed a GLP-1 drug. Our PubMed search for berberine patches found no human study that measured berberine in the blood. The drugs are too large to soak through intact skin, and the FDA drug database lists no skin route for any approved GLP-1 drug. The FTC lists claims of substantial weight loss from products worn on the skin as false.
Are there any weight loss patches that are actually effective?+
The FTC Gut Check guide says nothing you wear or apply to the skin can cause substantial weight loss, and it names patches as an example. In 2007 it banned one patch maker from selling weight loss patches. In the FDA drug database, approved GLP-1 drugs come only as shots or tablets.
What are the side effects of the weight loss patch?+
We found no trial that lists them, since none of the five labels named a study of its patch. Cleveland Clinic names two known concerns: a skin reaction to the patch itself, and unlisted ingredients that a buyer cannot check for. The FDA says it does not test dietary supplements before they are sold, and these patches are sold as supplements.
Do GLP-1 patches contain semaglutide or tirzepatide?+
Not on any label we read. All five listed plant extracts, vitamins or amino acids instead. The FDA lists no skin route for any approved GLP-1 drug, so a patch that claimed to hold one would be an unapproved drug.
Is a real GLP-1 patch being developed?+
Only in early research. Two animal studies, from 2024 and 2026, tested tiny needles loaded with semaglutide on rats. Those needles break the skin surface, which a sticker does not do. In the FDA drug database we searched, no approved GLP-1 drug lists a skin route.
Sources: US Federal Trade Commission, "Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims" (January 2014, read 23 October 2026): the guide covers patches, creams and wraps, and says nothing worn on the body or rubbed into the skin can cause substantial weight loss, and names patches among its examples.; US Federal Trade Commission press release, "Weight-Loss Patch Manufacturer Banned From Selling Weight-Loss Patches, Will Pay $180,000" (20 August 2007, read 23 October 2026): the order bars claims that a product worn or rubbed on the skin works for weight loss.; Cleveland Clinic Health Essentials, "Do GLP-1 Patches Actually Work?" (read 23 October 2026): unknown contents, the risk of unlisted ingredients, and skin reactions to the patch itself.; openFDA Drugs@FDA search run 23 October 2026 for semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, albiglutide and orforglipron: 32 application records, with routes listed as subcutaneous, injection or oral, and no skin or transdermal route.; Cheng X and colleagues. "Poly(vinyl alcohol) dissolving microneedles for transdermal semaglutide delivery and anti-obesity therapy in rats." International Journal of Pharmaceutics, online 21 October 2026. PMID 42906796, record checked on PubMed 23 October 2026. An animal study.; Singh P and colleagues. "Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity." Advanced Therapeutics, 2024. PMID 39429250. The full text says it was tested in rats.; US FDA, "Questions and Answers on Dietary Supplements" (content current as of 27 August 2026, read 23 October 2026): the FDA does not test dietary supplements before they are sold to consumers.; PubMed search run 23 October 2026: berberine AND (transdermal OR patch OR patches) gave 123 records. We read the titles of the 33 tagged as human research; none measured berberine in the blood after a patch was worn.; Peptides Vietnam label check, 23 October 2026: five GLP-1 patch product pages read by us, counts from our own notes.
Related pages
This page sums up product labels, regulator records and published research on GLP-1 patches. It is background, not medical advice, and it backs no product. For weight or blood sugar care, talk with a licensed doctor.